Oversight Chairman Greenwood Familiar With Third-Party Review Program
This article was originally published in The Gray Sheet
Executive Summary
Any legislative proposal to expand FDA's third-party review program to applications containing clinical data would have a powerful ally in Rep. Jim Greenwood (R-Penn.), the newly named chair of the House Energy and Commerce/Oversight Subcommittee.
You may also be interested in...
Legislative Oversight Of Device Third-Party Review Likely, Staffers Tell FDLI
Broader support on Capitol Hill to modify FDA's third-party review program in a way that would encourage greater utilization may hinge on members of Congress backing away from the larger issue of privatizing the agency.
Legislative Oversight Of Device Third-Party Review Likely, Staffers Tell FDLI
Broader support on Capitol Hill to modify FDA's third-party review program in a way that would encourage greater utilization may hinge on members of Congress backing away from the larger issue of privatizing the agency.
CDRH Is Lead Center For Ten Combination Product Reviews In FY 2000
FDA's Center for Devices and Radiological Health was the lead center in ten reviews conducted during FY 2000 on combination products in which the area of jurisdiction was not clearcut.